Advisory Services Network LLC Purchases 3,687 Shares of Becton, Dickinson and Company $BDX

Advisory Services Network LLC boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 26.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,449 shares of the medical instruments supplier’s stock after purchasing an additional 3,687 shares during the quarter. Advisory Services Network LLC’s holdings in Becton, Dickinson and Company were worth $3,110,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BDX. State of Wyoming bought a new stake in shares of Becton, Dickinson and Company during the second quarter valued at approximately $352,000. Asset Dedication LLC lifted its holdings in Becton, Dickinson and Company by 789.0% during the 2nd quarter. Asset Dedication LLC now owns 1,947 shares of the medical instruments supplier’s stock valued at $335,000 after purchasing an additional 1,728 shares during the last quarter. Liontrust Investment Partners LLP boosted its holdings in shares of Becton, Dickinson and Company by 25.9% in the 2nd quarter. Liontrust Investment Partners LLP now owns 626,449 shares of the medical instruments supplier’s stock worth $107,906,000 after acquiring an additional 128,900 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 5.2% during the second quarter. Geneos Wealth Management Inc. now owns 3,437 shares of the medical instruments supplier’s stock worth $592,000 after purchasing an additional 169 shares during the last quarter. Finally, Caxton Associates LLP bought a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $212,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $196.42 on Wednesday. The stock has a market capitalization of $56.06 billion, a PE ratio of 33.69, a P/E/G ratio of 1.85 and a beta of 0.25. The firm has a fifty day simple moving average of $189.15 and a 200 day simple moving average of $185.02. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.32 billion for the quarter. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 407 shares of company stock valued at $73,922. 0.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Royal Bank Of Canada dropped their target price on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $204.91.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.